An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany

European Journal of Health Economics

Volumn 8, Issue 2, 2007, Pages 153-160

  Sheriff, Sara K ^a   Petry, K Ulrich ^b   Ikenberg, Hans ^c   Crouse, Geoffrey ^d   Mazonson, Peter D ^a   Santas, Christopher C ^a  

^a Mosaic Health Care Consultants   (United States)

^b Klinikum der Stadt Wolfsburg   (Germany)

^c Laboratory for Cytology and Molecular Diagnostics   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cervical cancer; Cost effectiveness; Germany; Human papillomavirus; Pap smear

Indexed keywords

VIRUS DNA;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; ECONOMIC EVALUATION; FEMALE; GERMANY; HEALTH CARE SYSTEM; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; COSTS AND COST ANALYSIS; DECISION TREES; DISEASE MANAGEMENT; FEMALE; GERMANY; HUMANS; PAPILLOMAVIRIDAE; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 34248340968     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0038-5     Document Type: Article

References (25)

1. Ferlay, J., Bray, F., Pisani, P., Parkin, D.M.: GLOBOCAN 2002: Cancer Incidence, mortality and prevalence worldwide. IARCCancerBase No. 5. version 2.0, IARCPress, Lyon (2004)
2. Stenkvist, B., Bergstron, R., Eklund, G., Fox, C.H.: Papanicolaou smear screening and cervical cancer. What can you expect? J. Am. Med. Assoc. 252, 1423-1426 (1984)
3. Devesa, S.S., Silverman, D.T., Young, J.L., Pollack, E.S., Brown, C.C., Horm, J.W., et al.: Cancer incidence and mortality trends among whites in the United States, 1947-84. J. Natl. Cancer Inst. 79, 701-770 (1987)
4. Peto, J., Gilham, C., Fletcher, O., Matthews, F.E.: The cervical cancer epidemic that screening has prevented in the UK. Lancet 364, 249-256 (2004)
5. Gustafsson, L., Ponten, J., Zach, M., Adami, H.O.: International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 8, 755-763 (1997)
6. Sasieni, P., Adams, J.: Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age cohort model. BMJ 318, 1244-1245 (1999)
7. The ASCUS-LSIL Triage Study (ALTS) Group: Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 188, 1383-1392 (2003)
8. Schenck, U., Soost, H.J.: Nomenklatur und befundwiedergabe in der gynäkologischen zytologie. In: Referatband der 10. Fortbildungstagung für klinische Zytologie. München: Märkl-Druck 306-14 (1989)
9. Petry, K.U., Menton, S., Menton, M., van Loenen-Frosch, F., de Carvalho Gomes, H., Holz, B., et al.: Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8468 patients. Br. J. Cancer 88, 1570-1577 (2003)
10. Schneider, A., Hoyer, H., Lotz, B., Leistritza, S., Kuhne-Heid, R., Nindl, I., et al.: Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int. J. Cancer 89, 529-534 (2000)
11. Kinney, W.K., Manos, M.M., Hurley, L.B., Ransley, J.E.: Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet. Gynecol. 91, 973-976 (1998)
12. Beckmann, H. Interdisciplinary S2 guidelines for diagnosis and treatment of cervical carcinoma by the German Cancer Society (DKG) and the German Society for Gynecology and Obstetrics (DGGG)Deutsche Krebsgesellschaft E.V. (DKG) und Deutsche Gesellschaft für Gynäkologie und Geburtshifle (DGGG): Interdisziplinäre S-2 Leitlinie für die Diagnostik und Therapie des Zervixkarzinoms. Zuckschwerdt 1-47 (2004)
13. Weissenbacher, E.R., Schneider, A., Girardi, F., Gissmann, L., Gross, G., Heinrich, J., et al.:Empfehlungen zur diagnostik und therapie der HPV- infektion des weiblichen genitale. ESIDOG J. 4+5:3-12 (2001)
14. Walboomers, J.M., Jacobs, M.V., Manos, M.M., Manos, M.M., Bosch, F.X., Kummer, J.A., et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999)
15. Mitchell, M.F., Schottenfeld, D., Tortolero-Luna, G., Cantor, S.B., Richards-Kortum, R.: Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol. 91, 626-631 (1998)
16. Petry, K.U.: Zervixkarzinom: neue möglichkeiten zur prävention. MMP 27, 152-158 (2004)
17. Lonky, N.M., Felix, J.C., Naidu, Y.M., Wolde-Tsadik, G.: Triage of atypical cells of undetermined significance with hybrid capture II: colposcopy and histologic human papillomavirus correlation. Obstet. Gynecol. 01, 481-489 (2003)
18. Solomon, D., Schiffman, M., Tarone, R.: Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. 93 293-299 (2001)
19. Arbyn, M., Buntinx, F., Van Ranst, M., Paraskevaidis, E., Martin-Hirsch, P., Dillner, J.: Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl. Cancer Inst. 96, 280-293 (2004)
20. Kim, J.J., Wright, T.C., Goldie, S.J.: Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287, 2382-2390 (2002)
21. Kim, J., Wright, T., Goldie, S.: Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J. Natl. Cancer Inst. 97, 888-895 (2005)
22. Hughes, A., Glazner, J., Barton, P., Shlay, J.: A cost-effectiveness analysis of four management strategies in the determination and follow-up of atypical squamous cells of undetermined significance. Diagn. Cytopathol. 32, 125-132 (2005)
23. Shlay, J., Dunn, T., Byers, T., Baron, A., Douglas, J.: Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears. Obstet. Gynecol. 96, 410-416 (2000)
24. Guyot, A., Karim, S., Kyi, M., Fox, J.: Evaluation of adjunctive HPV testing by hybrid capture II in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy. BMC Infect. Dis. (2003), 23 (2003)
25. Holmes, J., Hemmett, L., Garfield, S.: The cost-effectiveness of human papillomavirus screening for cervical cancer. Eur. J. Health Econom. 50, 30-37 (2005)